Study	Reason for exclusion
Atad 1997	No short versus long duration infusions of paclitaxel comparison and study appears to be a case series.
Boddy 2000	Abstract of Boddy 2001 trial.
Boddy 2001	Cross over trial with a pharmacokinetic focus.
Calvert 1999	Trial does not report outcome measures as specified in protocol. The trial compares 1 hr versus 3 hr infusion but had a pharmacokinetic focus.
Connelly 1996	No short versus long duration infusions of paclitaxel comparison.
Gianni 1995	Trial seemed to vary carboplatin dose as well as duration of paclitaxel and had a pharmacokinetic focus.
Huizing 1993	Trial does not report outcome measures as specified in protocol. The trial compares 3 hr versus 24 hr infusion but had a pharmacokinetics focus.
Jennens 2003	Cross over trial.
Keung 1993	Abstract of Huizing 1993 trial.
Kudelka 1999	No short versus long duration infusions of paclitaxel comparison.
Mross 2002	Trial does not report outcome measures as specified in protocol. The trial compares 1 hr versus 3 hr infusion but had a pharmacokinetics focus.
Nannan 1999	Does not appear to be an RCT. The study compared 1 hr versus 3 hr infusion but had a pharmacokinetic focus. Tumour response was reported but five of the seven women in the 3 hr regimen crossed over to the 96 hr regimen as it was prespecified that patients not responding to the 3 hr schedule were permitted to cross over.
Rischin 1996	Cross over trial with a pharmacokinetic focus.
Sulkes 1994	Israeli experience of trials of duration of infusion of paclitaxel. Includes both breast (69 women) and ovarian cancer (38 women), but the breast cancer patients are likely to have been included in the report by Peretz (a co‐author of this paper). In addition no data on outcomes were presented.